PROTEASE-INHIBITORS · Serine proteinase inhibitors for therapy of inflammatory skin diseases
6РП — Действия „Мария Кюри“
- Период
- 2005-05-01 → 2009-04-30
- Финансиране от ЕС
- 600 996 €
- Участници
- 2
- Схема
- TOK
Линиите свързват координатора с партньорите.
Накратко на български
Сериновите протеинази и техните инхибитори се анализират, за да се разбере ролята им при заболявания като псориазис и атопичен дерматит. Това помага за разработването на нови лекарства за терапия на възпалителните кожни заболявания.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
Currently, no specific and causative therapy for the treatment of inflammatory skin diseases, e.g. atopic dermatitis and psoriasis, is available. To create new treatment options for these diseases, the applicants plan a strategic partnership by the mutual exchange of knowledge. Both the industrial partner, IPF PharmaCeuticals (Hannover, Germany), and the academic partner, Centro de Investigaciones Biologicas (Madrid, Spain), will contribute to the know-how transfer in the field of applied protein research for the examination of newly discovered serine proteinases and their inhibitors. A multi-domain serine proteinase inhibitor (LEKTI) was identified and was shown to play a significant role in the development of skin diseases. Based on these findings, the proposed research aims to examine the (patho-)physiological role of relevant serine proteinases and their pertinent inhibitors for the discovery of new drugs against skin diseases. The cooperation between the German company and the institution from the Spanish Council of Scientific Research (CSIC) will result in a long-lasting strategic partnership taking advantage of complementary know-how of each organization and of the different scientific and economic networks in these two countries of the EC.The applicants have a long-standing experience in the organization of scientific research collaborations, workshops, execution of scientific grants, publications, patent issues and in the exploition of intellectual property rights. This research co-operation plans (i) to identify and produce serine proteinases and their inhibitors related to atopic dermatitis and psoriasis, (ii) to elucidate their three-dimensional structure, (iii) on the basis of this knowledge to design optimized inhibitors, and (iv) to test the pharmacological potential of the inhibitors in animal models for skin diseases.
Оригинален текст от CORDIS (на английски).
Участници
Връзки
Данни: CORDIS, © Европейски съюз